Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 52, n° 3S
page P2 (mars 2005)
Doi : 10.1016/j.jaad.2004.10.022
Adalimumab in psoriatic arthritis: 24-week results of a phase III study
 

Philip Mease, MD, University of Washington School of Medicine, Seattle, WA, United States; Dafna Gladman, MD, University of Toronto, Toronto, ON, Canada; Christopher Ritchlin, MD, University of Rochester, Rochester, NY, United States; Mark Weinberg, MD, Abbott Laboratories, Abbott Park, IL, United States


 P6
Financial relationships with Abbott Laboratories: Dr. Mease writes research grants, receives consulting fees, and in on the Abbott Laboratories speaker's bureau. Dr. Gladman is a clinical investigator for and it on the advisory board of Abbott Laboratories. Dr. Ritchlin writes research grants for Abbott Laboratories. Dr. Weinberg is employed by Abbott Laboratories.
Abbott Laboratories supported this study and the printing of this poster.


Top of the page

© 2005  American Academy of Dermatology, Inc.@@#104156@@